My watch list
my.bionity.com  
Login  

6 Current news of Immunomedics

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

UCB announces start of phase III programme with epratuzumab for patients with moderate to severe systemic lupus erythematosus

Phase III programme follows positive phase IIb study EMBLEM, which showed that epratuzumab reduced disease activity over a 12 week treatment period

15-Dec-2010

UCB and U.S. based partner Immunomedics Inc. announced the enrollment of the first patient into EMBODY™ 1, one of two pivotal phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE). Patient enrollment for EMBODY™ 2 has also begun. Both studies ...

more

Epratuzumab phase IIb data show pipeline drug had positive effect in patients suffering from systemic lupus erythematosus

11-Nov-2010

UCB and U.S. based partner Immunomedics Inc.announced that results from the phase IIB study, EMBLEM™, showed that certain doses of epratuzumab were associated with a meaningful and statistically significant reduction in disease activity in adult patients with moderate to severe active SLE. The ...

more

Epratuzumab data from phase IIb EMBLEM study presented at 9th International Congress on Systemic Lupus Erythematosus

29-Jun-2010

UCB and Immunomedics Inc. announced that data for lupus drug candidate, epratuzumab, were presented at the 9th International Congress on Systemic Lupus Erythematosus in Vancouver, Canada. These data showed that, in patients with moderate to severe systemic lupus erythematosus (SLE), epratuzumab ...

more

New data from EMBLEM study shows epratuzumab provided efficacy for patients suffering from systemic lupus erythematosus

17-Jun-2010

UCB and Immunomedics Inc. announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the ...

more

UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE)

Data from phase IIb dose and regimen-ranging study demonstrate clinically meaningful treatment effect

28-Aug-2009

UCB and Immunomedics announced top-line results from UCB's Phase IIb clinical study comparing epratuzumab to placebo in patients with systemic lupus erythematosus (SLE, also commonly known as lupus). The data from the 12-week dose and regimen-ranging study demonstrated clinical meaningful ...

more

UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab

11-May-2006

UCB and Immunomedics, Inc. announced a collaboration and license agreement for Immunomedics' lead product, epratuzumab. The agreement grants UCB the exclusive worldwide rights to develop, market and sell epratuzumab for all autoimmune disease indications. Epratuzumab's most advanced program is ...

more

Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE